PDCD1 and glioblastoma: The field of immunotherapy offers promising new avenues6 with dendritic cell (DC) vaccinations7–10 or recent clinical trials targeting Programmed Cell Death protein-1 (PD-1) in order to regulate the immune checkpoint in GBM (ClinicalTrials.gov identifier: NCT02335918, NCT02529072).